AstraZeneca Adds Avanir Reverse Cholesterol Transport Program To Vascular Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca and Avanir plan to begin development of reverse cholesterol transport enhancing compounds in late 2005 under a deal worth up to $340 mil., the firms announced July 11